Overcoming Obesity 2023 (Live) -The Obesity Tipping Point: SELECT and the 2023 Wave of AOM Trials
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place. Let's look together at the trials and the new molecules that are changing the landscape of Obesity treatment. Agonists, Bi-agonists, Tri-agonists, Monoclonal Antibodies and more. Together, we will break it down to what's meaningful for Monday morning and how to get your clinic and your patients prepared for the future of anti-obesity medications.
Following the lecture given by Dr. Horn, there will be a Presidential Panel with current President Angela Fitch, Past-President Ethan Lazarus, Former President Craig Primack moderated by former President Deborah Horn.
CME/CE Expiration Date: 11/27/23
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
- Describe the SELECT trial design and primary outcome.
- Understand the SELECT baseline characteristics and top line data.
- Identify significant AOMs in the pipeline while evaluating the potential changes in societal attitudes towards obesity treatment.
Deborah Bade Horn, DO, MPH, MFOMA
Angela Fitch, MD, FACP, FOMA
Ethan Lazarus, MD, FOMA, AMA Delegate
Craig Primack, MD, FACP, FAAP, FOMA
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.